Cellestia Biotech

📍 Basel, Switzerland🗓 Founded 2014👥 19 employees💰 Last funded Jul 2022
Pharmaceutical Manufacturing🌐 cellestia.com
Website LinkedIn
Cellestia is a clinical stage R&D company developing innovative first-in-class therapies to control and modulate pathogenic gene expression in multiple disease areas by selective inhibition of transcription factors in the cell nucleus. The lead compound CB-103 has advanced to Phase 2 treating patients with multi-drug resistant cancers. Further, Cellestia is advancing a rich R&D pipeline of novel transcription factor inhibitors, in oncology, auto-immune and inflammatory disorders, having achieved animal in-vivo proof of concept for several new targets. Cellestia was founded in 2014 as a spin-off from EPFL, Lausanne, Switzerland and is headquartered in Basel, Switzerland.
2
Total investors
0
Early stage
1
Mid stage
1
Late stage
2014
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Switzerland
1
Frequently asked questions
Who invested in Cellestia Biotech?
Cellestia Biotech has 2 investors on record on gritt.io, 1 mid-stage and 1 late-stage investors.
When did Cellestia Biotech last raise funding?
The most recent investment in Cellestia Biotech recorded on gritt.io was in July 2022.
When was Cellestia Biotech founded?
Cellestia Biotech was founded in 2014.
What industry is Cellestia Biotech in?
Cellestia Biotech operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Cellestia Biotech based?
Cellestia Biotech is headquartered in Basel, Switzerland.